Rare tumour cells with mutations that confer drug resistance can go undetected by standard testing procedures, according to two studies, which show that such mutations can be detected in patients' blood. See Letters p.532 and p.537
This is a preview of subscription content, log in via an institution to check access.
References
Misale, S. et al. Nature 486, 532–536 (2012).
Diaz, L. A. Jr et al. Nature 486, 537–540 (2012).
Diehl, F. et al. Nature Methods 3, 551–559 (2006).
Montagut, C. et al. Nature Med. 18, 221–223 (2012).
Edkins, S. et al. Cancer Biol. Ther. 5, 928–932 (2006).
Marusyk, A., Almendro, V. & Polyak, K. Nature Rev. Cancer 12, 323–334, (2012).
Yap, T. A., Gerlinger, M., Futreal, P. A., Pusztai, L. & Swanton, C. Sci. Transl. Med. 4, 127ps10 (2012).
Gerlinger, M. et al. N. Engl. J. Med. 366, 883–892 (2012).
Diehl, F. et al. Nature Med. 14, 985–990 (2008).
Forshew, T. et al. Sci. Transl. Med. 4, 136ra68 (2012).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Vilar, E., Tabernero, J. Pinprick diagnostics. Nature 486, 482–483 (2012). https://doi.org/10.1038/486482a
Published:
Issue Date:
DOI: https://doi.org/10.1038/486482a
- Springer Nature Limited
This article is cited by
-
Tumour heterogeneity: principles and practical consequences
Virchows Archiv (2016)
-
Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology (2015)